- Conditions
- Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
- Interventions
- Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain Metastases, Small Cell Lung Cancer
- Interventions
- NovoTTF-200A, Stereotactic Radiosurgery (SRS)
- Device · Radiation
- Lead sponsor
- Drexell Hunter Boggs
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
- Interventions
- CC-486, Carboplatin, ABI-007
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more
- Conditions
- Cancer
- Interventions
- vorinostat
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors
- Interventions
- ME-344, Topotecan
- Drug
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Interventions
- FR901228
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer
- Interventions
- biricodar dicitrate, doxorubicin hydrochloride, vincristine sulfate
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Indianapolis, Indiana • Boston, Massachusetts + 5 more
- Conditions
- Cancer
- Interventions
- recombinant adenovirus-hIFN-beta
- Biological
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Biological
- Lead sponsor
- H. Kim Lyerly
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Durham, North Carolina
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- TRAIL-R1 mAb (TRM-1;HGS-ETR1)
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Durham, North Carolina + 2 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Dinutuximab, Irinotecan, Topotecan
- Biological · Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 40
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Tucson, Arizona + 35 more
- Conditions
- Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2008
- U.S. locations
- 72
- States / cities
- Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
- Conditions
- Lung Cancer
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Cleveland, Ohio
- Conditions
- Lung Cancer
- Interventions
- IPI-504
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 11
- States / cities
- Los Angeles, California • New Haven, Connecticut • Miami, Florida + 6 more
- Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- ofatumumab, ibrutinib
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Interventions
- Docetaxel, Tergenpumatucel-L, Indoximod
- Drug · Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Cincinnati, Ohio
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706, Topotecan, Lurbinectedin, Amrubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 27 more
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Amifostine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 15
- States / cities
- Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Recurrent Small Cell Lung Carcinoma, Refractory Small Cell Lung Carcinoma, Lung Cancer Stage IV, Large Cell Neuroendocrine Carcinoma, Neuroendocrine Tumors, Small Cell Lung Cancer Metastatic, Small-cell Lung Cancer
- Interventions
- Nivolumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Small Cell Lung Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study, Topotecan Hydrochloride
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
- Interventions
- NIZ985, Spartalizumab, Tislelizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Duarte, California • La Jolla, California